8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2021 / Randomized controlled trial
In the DIRECT PLUS trial, participants lost weight over 6 months on healthy guidelines, a Mediterranean diet, or a green-Mediterranean diet. Ninety participants provided fecal samples collected at month 6 and were randomized to receive capsules containing their own fecal microbiota (aFMT) or placebo until month 14. Across all participants, aFMT did not significantly reduce weight regain versus placebo (30.4% vs 40.6%, P = .28), but it significantly attenuated regain in the green-Mediterranean group (17.1% vs 50%, P = .02; P for interaction = .03). In this group, aFMT also reduced waist circumference gain (1.89 cm vs 5.05 cm, P = .01) and insulin rebound (P = .04).
Rinott E, Youngster I, Yaskolka Meir A, et al. Gastroenterology, 2021. PMID 32860791
2021 / Randomized, double-blind, crossover trial
Sixteen overweight older adults consumed a high-fat high-energy meal with 250 mL of either anthocyanin-rich Queen Garnet Plum juice or control apricot juice in a randomized crossover trial. Compared to control, the anthocyanin arm had higher 2-hour postprandial flow-mediated dilatation (+1.14%, P = 0.019) and higher microvascular post-occlusive reactive hyperaemia (+0.10 perfusion units per mmHg, P = 0.049). C-reactive protein was lower at 4 hours postprandially in the anthocyanin arm (1.80 mg/L) compared with control (2.30 mg/L, P = 0.026). No significant postprandial differences were found for blood pressure, lipids, oxidative metabolites, or other inflammatory markers.
do Rosario VA, Chang C, Spencer J, et al. Clin Nutr, 2021. PMID 33071012
2021 / Three-group randomized crossover trial
In a randomized crossover study, 60 men (with type 2 diabetes, overweight/obese, or healthy controls) consumed an energy- and macronutrient-matched vegan meal (V-meal) or conventional meat meal (M-meal). Thalamus perfusion decreased significantly after the M-meal in men with type 2 diabetes (p = 0.04) and overweight/obese men (p = 0.004), but decreased significantly after the V-meal in healthy controls (p < 0.001). Postprandial active GLP-1 secretion was higher after the V-meal compared with the M-meal by 42% in men with type 2 diabetes (p = 0.003) and by 41% in healthy controls (p = 0.002). Changes in thalamus perfusion after the meals correlated with changes in satiety (r = +0.68; p < 0.01).
Kahleova H, Tintera J, Thieme L, et al. Clin Nutr, 2021. PMID 33081982
2021 / Randomized, double-blind, placebo-controlled crossover trial
A randomized, double-blind, placebo-controlled crossover trial evaluated 12 weeks of once-daily oral semaglutide versus placebo in 15 subjects with type 2 diabetes. In 13 evaluable subjects, total daily ad libitum energy intake was significantly lower by 38.9% with oral semaglutide versus placebo (estimated treatment difference: -5096.0 kJ; 95% CI -7000.0, -3192.1; P = .0001). Satiety, hunger, and overall appetite scores significantly favored semaglutide after a fat-rich breakfast, alongside fewer food cravings and better eating control. Mean body weight decreased by 2.7 kg with oral semaglutide compared to 0.1 kg with placebo, primarily due to loss of body fat mass.
Gibbons C, Blundell J, Tetens Hoff S, et al. Diabetes Obes Metab, 2021. PMID 33184979
2021 / Randomized controlled trial
A randomized controlled trial assigned 48 obese women with PCOS to receive a low-calorie diet with either 5 g/day thylakoid-rich spinach extract or 5 g/day placebo for 12 weeks. Compared to placebo, the spinach extract group had a greater increase in serum omentin-1 (10.90 vs. 3.87 ng/L; p < .001) and greater reductions in fat mass (-5.19 vs. -1.35 kg; p < .001), neopterin (-0.66 vs. -0.38 nmol/L; p = .003), and chemerin (-41.24 vs. -11.26 ng/L; p < .001). Significant decreases in other anthropometric indices and insulin resistance were also observed in the thylakoid group compared to placebo (p < .001 for all parameters).
Pourteymour Fard Tabrizi F, Abbasalizad Farhangi M, Vaezi M, et al. Phytother Res, 2021. PMID 33368745
2021 / Randomized crossover inpatient trial
Twenty inpatients were randomized to consume ad libitum either a minimally processed, plant-based, low-fat diet (10.3% fat, 75.2% carbohydrate) or an animal-based, ketogenic, low-carbohydrate diet (75.8% fat, 10.0% carbohydrate) for 2 weeks, followed immediately by the alternate diet. One participant withdrew due to hypoglycemia during the low-carbohydrate diet. The low-fat diet led to 689 ± 73 kcal d-1 less energy intake over 2 weeks (P < 0.0001) and 544 ± 68 kcal d-1 less over the final week (P < 0.0001) compared to the low-carbohydrate diet.
Hall KD, Guo J, Courville AB, et al. Nat Med, 2021. PMID 33479499
2021 / Randomized, double-blind, placebo-controlled crossover trial & in vitro study
Researchers investigated the effects of nicotinamide riboside (NR) on brown adipose tissue (BAT) in mice, in vitro human adipocytes, and human volunteers. In vitro, NR enhanced norepinephrine-stimulated mitochondrial uncoupling in primary adipocytes from human BAT. However, in a randomized, double-blind, placebo-controlled crossover study of human volunteers receiving 1000 mg/day NR for 6 weeks, NR supplementation did not alter in vivo BAT activity or cold-induced thermogenesis.
Nascimento EBM, Moonen MPB, Remie CME, et al. J Clin Endocrinol Metab, 2021. PMID 33524145
2021 / Double-blind randomized controlled trial
In a double-blind trial, 1961 adults with overweight or obesity without diabetes were randomly assigned (2:1) to 68 weeks of once-weekly subcutaneous semaglutide (2.4 mg) or placebo, both combined with lifestyle intervention. Mean body weight change was -14.9% with semaglutide compared to -2.4% with placebo (difference -12.4 percentage points; P<0.001), representing a -15.3 kg vs. -2.6 kg change. Significantly more semaglutide participants achieved weight reductions of ≥5% (86.4% vs. 31.5%), ≥10% (69.1% vs. 12.0%), and ≥15% (50.5% vs. 4.9%). Transient, mild-to-moderate nausea and diarrhea were the most common adverse events, with 4.5% of semaglutide participants discontinuing treatment due to gastrointestinal events versus 0.8% with placebo.
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med, 2021. PMID 33567185
2021 / Randomized controlled trial
In a randomized trial, 78 women aged 18-40 years with PCOS received either 1000 mg resveratrol or 1000 mg placebo daily for 3 months. Compared to placebo, the resveratrol group had a significantly higher regular menstruation rate (76.47% vs. 51.61%; p = 0.03) and lower hair loss (32.10% vs. 68.00%; p = 0.009). No significant differences were found between groups for ovarian and adrenal androgens, SHBG, FAI, glycoinsulinemic metabolism, or lipid profile, and weight did not change relative to placebo.
Mansour A, Samadi M, Sanginabadi M, et al. Clin Nutr, 2021. PMID 33610422
2021 / Randomized, double-blind, parallel-group trial
A 68-week trial randomized 611 adults with overweight or obesity to once-weekly subcutaneous semaglutide (2.4 mg) or placebo, both combined with intensive behavioral therapy and an initial 8-week low-calorie diet. At week 68, estimated mean body weight change was -16.0% with semaglutide compared to -5.7% with placebo (difference: -10.3 percentage points, P < .001). Significantly more participants in the semaglutide group achieved weight losses of at least 5% (86.6% vs 47.6%), 10% (75.3% vs 27.0%), and 15% (55.8% vs 13.2%). Gastrointestinal adverse events occurred in 82.8% of semaglutide participants versus 63.2% with placebo, causing discontinuation in 3.4% and 0%, respectively.
Wadden TA, Bailey TS, Billings LK, et al. JAMA, 2021. PMID 33625476
2021 / Randomized, double-blind, double-dummy, placebo-controlled trial
In this 68-week trial, 1210 adults with type 2 diabetes and a BMI of at least 27 kg/m2 were randomized to receive weekly subcutaneous semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo, alongside a lifestyle intervention. Estimated mean bodyweight change was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo (difference -6.2 percentage points, 95% CI -7.3 to -5.2; p<0.0001). Significantly more patients taking semaglutide 2.4 mg achieved at least 5% weight reduction compared to placebo (68.8% vs 28.5%; OR 4.88, 95% CI 3.58 to 6.64; p<0.0001). Adverse events, particularly gastrointestinal events, were more common with semaglutide 2.4 mg (87.6% total, 63.5% gastrointestinal) than with placebo (76.9% total, 34.3% gastrointestinal).
Davies M, Færch L, Jeppesen OK, et al. Lancet, 2021. PMID 33667417
2021 / Randomized, double-blind, phase 3a withdrawal trial
Following a 20-week run-in with subcutaneous semaglutide resulting in a mean weight loss of 10.6%, 803 participants were randomized to 48 weeks of continued semaglutide (2.4 mg/week) or placebo, both with lifestyle intervention. From week 20 to 68, participants continuing semaglutide had a mean weight change of -7.9% compared to +6.9% with placebo (difference: -14.8 percentage points, P < .001). Continued semaglutide also led to greater improvements in waist circumference (-9.7 cm), systolic blood pressure (-3.9 mm Hg), and physical functioning scores. Gastrointestinal adverse events were reported in 49.1% of semaglutide participants versus 26.1% with placebo, though discontinuation rates due to adverse events were similar (2.4% vs 2.2%).
Rubino D, Abrahamsson N, Davies M, et al. JAMA, 2021. PMID 33755728
2021 / 10-week randomized, placebo-controlled, double-blind trial
A 10-week, randomized, placebo-controlled, double-blind trial evaluated the effects of nicotinamide mononucleotide (NMN) supplementation on metabolic function in overweight or obese postmenopausal women with prediabetes. Insulin-stimulated glucose disposal, evaluated using a hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling (AKT and mTOR phosphorylation) increased after NMN supplementation but did not change after placebo. Additionally, NMN supplementation up-regulated platelet-derived growth factor receptor β and other genes involved in muscle remodeling.
Yoshino M, Yoshino J, Kayser BD, et al. Science, 2021. PMID 33888596
2021 / Double-blind, randomized, placebo-controlled trial
A double-blind, placebo-controlled trial evaluated daily supplementation with a fruit and vegetable concentrate (FVC) and high-fiber component across 57 pre-menopausal, overweight/obese female healthcare workers over five months. FVC supplementation had no effect on blood lipids, glucose, or immune parameters, but improved glucose clearance. FVC did not alter phyla-level taxonomy or alpha/beta diversity, but reduced Bacteroides abundance and increased fecal butyrate; adding a high-fiber component improved levels of health-associated bacteria.
van der Merwe M, Moore D, Hill JL, et al. Microorganisms, 2021. PMID 33920059
2020 / Single-blinded randomized pilot study
Forty participants with type 2 diabetes mellitus were randomized to 3 months of either yoga (postures and breathing exercises, n = 20) or sham yoga (nonaerobic stretching, n = 20). Both groups demonstrated significant within-group improvements in malondialdehyde, vitamin C, superoxide dismutase, fasting blood glucose, glycosylated hemoglobin, body mass index, waist circumference, and blood pressure. Yoga participants showed significantly greater improvement in reduced glutathione compared to controls, but no other significant differences between groups were observed.
Hegde SV, Adhikari P, Kotian SM, et al. Int J Yoga Therap, 2020. PMID 31283365
2020 / Randomized controlled trial
In a 12-week randomized, double-blind, placebo-controlled trial of 70 overweight adults, taking steamed onion capsules before each meal significantly decreased body fat percentage (p = 0.028) and total fat mass (p = 0.022) measured by DEXA. Computed tomography scans showed significant drops in visceral, subcutaneous, and whole fat areas at L1 and L4. Steamed onion intake also significantly reduced serum triglycerides and C-peptide levels without altering lean body mass.
Jeong S, Chae J, Lee G, et al. J Am Coll Nutr, 2020. PMID 31368861
2020 / Pre-post intervention study
An experiential education program was conducted with 30 nurse practitioners, registered nurses, and physicians who followed a whole-food plant-based (WFPB) diet for 3 weeks. Preintervention and postintervention questionnaires assessed various health and professional outcomes. Participants decreased their intake of animal-derived foods, increased WFPB food intake, lost weight, and experienced improvements in mood and energy. Additionally, perceived barriers to following and counseling about a WFPB diet declined, self-efficacy improved, and participants were likely to continue the diet and discuss it with patients.
Lessem A, Gould SM, Evans J, et al. J Am Assoc Nurse Pract, 2020. PMID 31577667
2020 / Randomized, placebo-controlled clinical trial
In a randomized, placebo-controlled trial, 40 middle-aged, obese, insulin-resistant men received 1000 mg nicotinamide riboside (NR) or placebo twice daily for 12 weeks. NR supplementation decreased NAMPT protein levels in skeletal muscle by 14%, but steady-state NAD+ levels and other biosynthetic enzymes were unchanged. NR did not affect skeletal muscle mitochondrial respiratory capacity, mitochondrial-associated protein abundance, mitochondrial fractional area, or network morphology.
Dollerup OL, Chubanava S, Agerholm M, et al. J Physiol, 2020. PMID 31710095
2020 / 3-month self-selection pilot trial
A 3-month self-selection pilot study evaluated a watermelon-focused Inflammation Management Intervention (n = 15) versus basic health education controls (n = 8). There were no group-by-time interactions for any studied outcomes. Post hoc analyses grouped participants by change in energy-adjusted Dietary Inflammatory Index (E-DII) score, noting that some intervention participants became more proinflammatory and several controls became more anti-inflammatory. Those with more anti-inflammatory dietary changes (below median E-DII change) showed differences in body fat percent (-1.27% vs +0.90%, P = .01), BMI (-0.66 vs +0.38 kg/m2, P = .06), and body weight (-0.99 vs +0.54 kg, P = .08).
Wirth MD, Shivappa N, Khan S, et al. Nutr Metab Insights, 2020. PMID 31975781
2020 / Randomized double-blind placebo-controlled pilot trial
In a 12-week pilot trial, 24 adults with obesity and mild-moderate insulin resistance were randomized to weekly oral FMT capsules from healthy lean donors or placebo for 6 weeks. There were no statistically significant improvements in insulin sensitivity between groups (+5% ± 12% in FMT vs -3% ± 32% in placebo, mean difference 9%, 95% CI -5% to 28%, p = 0.16). Additionally, no significant differences were seen for HOMA-IR (mean difference 0.2, 95% CI -0.9 to 0.9, p = 0.96), lean mass (mean difference -0.1 kg, p = 0.87), or fat mass (mean difference 1.2 kg, p = 0.18). Variable bacterial engraftment persisted throughout 12 weeks with no serious adverse events related to FMT.
Yu EW, Gao L, Stastka P, et al. PLoS Med, 2020. PMID 32150549
2020 / Randomized, double-blinded, placebo-controlled, crossover trial
In a randomized, double-blinded, placebo-controlled crossover study, 13 healthy overweight or obese adults received 1000 mg/d nicotinamide riboside (NR) and placebo for 6 weeks each. NR increased skeletal muscle markers of NAD+ synthesis, body fat-free mass (62.65% ± 2.49% vs 61.32% ± 2.58%; change: 1.34% ± 0.50%, P = 0.02), and sleeping metabolic rate. Skeletal muscle acetylcarnitine concentrations increased (4558 ± 749 vs 3025 ± 316 pmol/mg dry weight; change: 1533 ± 683, P = 0.04), along with exercise acetylcarnitine-forming capacity (P = 0.01). However, NR had no effects on insulin sensitivity, mitochondrial function, hepatic/intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, blood pressure, inflammation markers, or energy metabolism.
Remie CME, Roumans KHM, Moonen MPB, et al. Am J Clin Nutr, 2020. PMID 32320006
2020 / Randomized controlled intervention study
In Slovenia during winter, 105 healthy adults with suboptimal vitamin D status (25-OH-VitD 30-50 nmol/L) were randomized to three daily cholecalciferol formulations (1000 IU/25 µg as capsules, oil-based spray, or water-based spray) or a control group for two months. Supplementation significantly increased serum 25-OH-VitD levels compared to control (pooled Δc 32.8 nmol/L; 95% CI: 23.0, 42.5, p < 0.0001), with no significant differences between the formulations. Supplementation efficiency was associated with body mass index and baseline 25-OH-VitD, showing higher efficiency in participants with BMI < 25 and those with more pronounced insufficiency. The tested dosage was not sufficient to reach recommended levels in all subjects.
Žmitek K, Hribar M, Hristov H, et al. Nutrients, 2020. PMID 32365732
2020 / Two-period randomized crossover trial
In a randomized crossover trial, 55 adults with elevated BMI and cardiometabolic risk consumed 3/4 cup/day of mixed dried fruits (plums, figs, dates, raisins) or an isocaloric, carbohydrate-matched control snack for 4 weeks. Lipid and lipoprotein concentrations did not differ between conditions, though dried fruit increased LDL-cholesterol from baseline (0.10 mmol/l, 95% CI 0.01, 0.20). Compared with control, dried fruit increased mean fasting glucose (0.08 mmol/l, 95% CI 0.005, 0.16; P = 0.038), while vascular outcomes, fasting insulin, and C-reactive protein did not differ. Mean weight changes did not differ between groups (P = 0.55), but tended to increase in both.
Sullivan VK, Petersen KS, Kris-Etherton PM Br J Nutr, 2020. PMID 32513313
2020 / Randomized crossover trial
In the SWAP-MEAT crossover trial, 36 healthy adults consumed ≥2 servings/day of plant-based alternative meat versus animal meat for 8 weeks each with no washout period. Overall mean ± SEM TMAO concentrations were lower during the plant phase (2.7 ± 0.3 vs. 4.7 ± 0.9 µM, P = 0.012), though a significant order effect occurred; TMAO was significantly lower only in participants receiving plant meat second. LDL-cholesterol concentrations (109.9 ± 4.5 vs. 120.7 ± 4.5 mg/dL, P = 0.002) and body weight (78.7 ± 3.0 vs. 79.6 ± 3.0 kg, P < 0.001) were also significantly lower during the plant-based phase.
Crimarco A, Springfield S, Petlura C, et al. Am J Clin Nutr, 2020. PMID 32780794